🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Large Scale proteomics is opening the door to identify novel biomarkers for complex disease. In this study we used Machine learning approaches and CSF proteomics to create predictive models for Amyloid and Tau-PET stages. cell.com/cell-reports-m… WashU Medicine Knight ADRC WashU Medicine Neurology

NIH funding cuts could cost the U.S. $16 Billion and 68,000 jobs. An interactive tool from Joshua Weitz and team shows the local impact across the U.S. - down to the county level. This isn’t abstract - these numbers affect real communities and real lives: scienceimpacts.org

We now have a blood biomarker that is even more strongly associated with tau PET and cognitive symptoms than even p-tau217! eMTBR-tau243 will help us to understand whether cognitive impairment is likely to be related to Alzheimer's pathology. #ENDALZ nature.com/articles/s4159…

Here's what to know about a new Alzheimer's blood test time.com/7273006/alzhei…

New Alzheimer blood biomarker! Plasma eMTBR-tau243 correlates strongly with tau tangle pathology, brain atrophy and cognitive decline. I believe it will complement p-tau217 in clinical practice and in many trials. rdcu.be/efPge

Great new study out in Nature Medicine identifies #Plasma eMTBR-tau243 as a specific #biomarker of #tau tangles in #Alzheimers disease, enabling the detecting and tracking of Alzheimer’s clinical impairment. #ADPD2025 nature.com/articles/s4159…

🚨New publication in Nature Medicine, co-led with Kanta Horie🚨 Huge step towards an accurate and scalable diagnosis for #Alzheimer's disease. In this study, we validated the novel MTBR-tau243 biomarker in plasma🩸 A short 🧵

Nice work by Vincent Bouteloup, Nicolas Villain, Vincent Planche, and others: Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers jamanetwork.com/journals/jaman…

Can WashU Medicine stop Alzheimer’s before it starts? Could an "escape patient"— someone who was destined to develop Alzheimer’s but didn’t — hold the key to a breakthrough? Could our recent clinical trial pave the way for a drug that prevents Alzheimer’s? Learn more.

Glucose-lowering therapy with GLP1-RAs, but not SGLT2 inhibitors, was associated with a statistically significant reduction in dementia or cognitive impairment. ja.ma/42h4Ca3

So proud of Barcelonaβeta Brain Research Center and BioFINDER teams for this very important work on validating an easily-available plasma biomarker for #Alzheimer's diagnosis. Special kudos to my PhD student Noëlle Warmenhoven, co-first author of the paper👏👏👏

We're entering a new era of #Alzheimers blood testing—fully automated platforms now deliver fast, accurate #pTau217 results for use in primary & secondary care. Proud to share senior authorship and proud of this multi-centre European collaboration. 🔗 nature.com/articles/s4159…

New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’s disease (AD) pathology?🩸 Our new multi-cohort study has now been published in Nature Medicine: nature.com/articles/s4159…. A thread🧵

Important article for the field available in open access: Donanemab: Appropriate use recommendations. G.D. Rabinovici et al. sciencedirect.com/science/articl… #Donanemab jpreventionalzheimer

Lecanemab has been approved in Europe—the first disease-modifying treatment for #Alzheimer . Now, from public health centers, we must ensure equitable access, minimize risks, and offer the best care. 🧠🏥💚 Barcelonaβeta Brain Research Center Fundación Pasqual Maragall Hospital del Mar ec.europa.eu/newsroom/sante…

Our comments on the new #blood tests for #Alzheimers #disease which are increasingly improving and becoming applicable to clinical use. We should use them but use them in the correct way. nature.com/articles/d4158…

Materials and Methods sections in scientific papers:

A highly accurate, new blood test developed by #WashUMedicine and Lund University can diagnose Alzheimer's and indicate its progression by measuring MTBR-tau243 protein levels. This advancement could help tailor treatment plans. bit.ly/4jaXov0

Thank you 60 Minutes for giving the devastating NIH pauses and proposed budget cuts the attention they deserve. ALL Americans regardless of party affiliation will be impacted, and the impact goes long beyond one administration. cbsnews.com/video/nih-cuts…

Check out a great podcast featuring Joe Therriault explaining how to diagnose Alzheimer's disease by integrating the clinical impression with plasma biomarkers: pca.st/episode/b729fe… He makes PPV/NPV so easy to understand! From his recent paper: rdcu.be/eldzt